US to import short-supply cancer drug from India

US to import short-supply cancer drug from India

US health authorities said today they will import a drug to treat ovarian, bone marrow and AIDS-related skin cancer from India in order to ward off a worrying shortage.

"Lipodox will be imported as an alternative to Doxil," the US Food and Drug Administration said in a statement, noting that a temporary deal has been made with Sun Pharma Global FZE in India to supply US patients with the drug.

"Temporary importation of unapproved foreign drugs is considered in rare cases when there is a shortage of an approved drug that is critical to patients and the shortage cannot be resolved in a timely fashion with FDA-approved drugs."

Another drug that has been in short supply, methotrexate, needed for treating a variety of cancers including children with leukemia, was approved in preservative-free generic form for maker APP Pharmaceuticals in Illinois and should be available by March, the FDA said.

In the meantime, a shipment of 31,000 vials, or one month's supply, is being sent right away to hundreds of US hospitals and treatment centres by Hospira, the agency added.
Prescription drug shortages in the United States nearly tripled from 2005 to 2010, according to the Department of Health and Human Services.

Many drugs are falling out of production because drugmakers cannot profit when medications go generic and carry extremely low price tags. Profit-incentive for doctors to prescribe more expensive cancer meds has also contributed to the problem.

In October 2011, US President Barack Obama signed an executive order directing action to head off shortages in life-saving prescription drugs.

Obama's order strengthened the FDA's power to predict and tackle potential shortages of prescription drugs and to halt illegal price gouging of life-saving medicines during supply shortfalls.

Since then, the FDA has been able to ward off 114 drug shortages, compared to a total of 195 drug shortages prevented in 2011, the agency said.

The change is mostly due to a six-fold increase in companies complying with a request to give early warning to the FDA if they foresee a shortage, so that health authorities can seek other suppliers.

The FDA today also "issued draft guidance to industry on detailed requirements for both mandatory and voluntary notifications to the agency of issues that could result in a drug shortage or supply disruption," it said.